Float Short %

3.42

Margin Of Safety %

Put/Call OI Ratio

1.46

EPS Next Q Diff

-1.34

EPS Last/This Y

3.14

EPS This/Next Y

1.63

Price

128.69

Target Price

177.26

Analyst Recom

1.38

Performance Q

-7.21

Upside

27.1%

Beta

0.32

Ticker: NBIX

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	NBIX	136.15	1.52	4.24	8864
2026-01-26	NBIX	134.52	1.51	0.89	9274
2026-01-27	NBIX	133.94	1.51	1.17	9291
2026-01-28	NBIX	134.65	1.51	0.95	9314
2026-01-29	NBIX	137.9	1.53	0.44	9449
2026-01-30	NBIX	136.14	1.52	1.33	9447
2026-02-02	NBIX	137.62	1.52	0.85	9448
2026-02-03	NBIX	138.94	1.52	2.06	9466
2026-02-05	NBIX	137.93	1.54	2.63	9586
2026-02-09	NBIX	139.62	1.58	0.63	9524
2026-02-10	NBIX	137.65	1.58	0.38	9527
2026-02-11	NBIX	137.38	1.59	0.92	9526
2026-02-12	NBIX	122.94	1.57	5.43	9533
2026-02-13	NBIX	124.06	1.29	27.41	9546
2026-02-17	NBIX	127.79	1.43	1.85	10136
2026-02-18	NBIX	128.34	1.46	1.23	11002
2026-02-19	NBIX	130.06	1.46	70.71	11011
2026-02-20	NBIX	128.62	1.46	0.09	11015
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	NBIX	136.18	39.6	475.2	6.92
2026-01-26	NBIX	134.50	39.6	471.0	6.92
2026-01-27	NBIX	133.91	38.6	479.9	6.92
2026-01-28	NBIX	134.73	38.6	492.0	6.92
2026-01-29	NBIX	137.98	38.6	512.7	6.92
2026-01-30	NBIX	136.14	38.6	470.3	6.92
2026-02-02	NBIX	137.64	38.2	498.0	6.92
2026-02-03	NBIX	139.01	37.5	496.2	6.92
2026-02-04	NBIX	137.82	36.8	475.6	6.92
2026-02-05	NBIX	137.89	36.8	485.2	6.92
2026-02-06	NBIX	141.27	36.8	512.6	6.92
2026-02-09	NBIX	139.58	36.3	472.1	6.92
2026-02-10	NBIX	137.70	36.3	469.9	6.92
2026-02-11	NBIX	137.48	36.3	483.1	6.92
2026-02-12	NBIX	123.03	36.3	365.3	6.92
2026-02-13	NBIX	124.19	174.2	495.2	8.71
2026-02-17	NBIX	127.79	152.6	215.6	8.11
2026-02-18	NBIX	128.34	152.6	191.9	8.11
2026-02-19	NBIX	130.06	146.7	200.0	7.95
2026-02-20	NBIX	128.69	146.7	-	7.95
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	NBIX	-7.26	-0.96	4.54
2026-01-26	NBIX	-7.26	-0.94	4.19
2026-01-27	NBIX	-7.26	-0.94	4.19
2026-01-28	NBIX	-7.26	-0.94	3.61
2026-01-29	NBIX	-7.26	-0.94	3.61
2026-01-30	NBIX	-7.26	-0.94	3.61
2026-02-02	NBIX	-7.26	-0.91	3.61
2026-02-03	NBIX	-7.26	-0.91	3.61
2026-02-04	NBIX	-7.26	-0.91	3.61
2026-02-05	NBIX	-7.26	-0.91	3.61
2026-02-06	NBIX	-7.26	-0.91	3.61
2026-02-09	NBIX	-7.26	0.21	3.61
2026-02-10	NBIX	-7.23	0.21	3.61
2026-02-11	NBIX	-7.23	0.21	3.44
2026-02-12	NBIX	-3.66	0.21	3.44
2026-02-13	NBIX	-3.66	0.21	3.44
2026-02-17	NBIX	-3.64	1.70	3.42
2026-02-18	NBIX	-3.64	1.70	3.42
2026-02-19	NBIX	-3.64	1.70	3.42
2026-02-20	NBIX	-3.64	1.70	3.42
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

3.33

Avg. EPS Est. Current Quarter

1.73

Avg. EPS Est. Next Quarter

1.99

Insider Transactions

-3.64

Institutional Transactions

1.7

Beta

0.32

Average Sales Estimate Current Quarter

771

Average Sales Estimate Next Quarter

848

Fair Value

132.79

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

19.7

Max Drawdown 5-Year %

-42.9

Target Price

177.26

P/E

27.56

Forward P/E

17.15

PEG

0.62

P/S

4.51

P/B

3.96

P/Free Cash Flow

17.24

EPS

4.67

Average EPS Est. Cur. Y

7.95

EPS Next Y. (Est.)

9.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.73

Relative Volume

0.96

Return on Equity vs Sector %

-14.3

Return on Equity vs Industry %

7.5

EPS 1 7Days Diff

-1.2

EPS 1 30Days Diff

-1.19

EBIT Estimation

Neurocrine Biosciences, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 2000

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today

news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance

stock history NBIX – Neurocrine Biosciences, Inc. invest stock market

stock prices NBIX premarket after hours

ticker NBIX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NBIX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y